Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun 19;117(1):80-8.
doi: 10.1161/CIRCRESAHA.117.305365.

Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes

Affiliations
Review

Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes

Ioannis Karakikes et al. Circ Res. .

Abstract

Disease models are essential for understanding cardiovascular disease pathogenesis and developing new therapeutics. The human induced pluripotent stem cell (iPSC) technology has generated significant enthusiasm for its potential application in basic and translational cardiac research. Patient-specific iPSC-derived cardiomyocytes offer an attractive experimental platform to model cardiovascular diseases, study the earliest stages of human development, accelerate predictive drug toxicology tests, and advance potential regenerative therapies. Harnessing the power of iPSC-derived cardiomyocytes could eliminate confounding species-specific and interpersonal variations and ultimately pave the way for the development of personalized medicine for cardiovascular diseases. However, the predictive power of iPSC-derived cardiomyocytes as a valuable model is contingent on comprehensive and rigorous molecular and functional characterization.

Keywords: cardiovascular disease modeling; cardiovascular diseases; induced pluripotent stem cells; myocytes, cardiac; precision medicine.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Current applications of patient-specific iPSC-CM technology
iPSC-CMs have been used for disease modeling of inherited cardiomyopathies and channelopathies, regenerative therapies, drug discovery and cardiotoxicity testing, as well as for studying metabolic abnormalities and cardiac development.
Figure 2
Figure 2. Expression of key structural and functional genes in iPSC-CMs
A) Schematic of the major structural and functional features of iPSC-CMs. In adult CMs, upon membrane depolarization a small amount of Ca2+ influx induced by activation of voltage-dependent L-type Ca2+ channels (CACNAC1) triggers the release of Ca2+ through the ryanodine receptors (RYR2) SR, termed Ca2+-induced Ca2+-release (CICR) mechanism. The released Ca2+ ions diffuse through the cytosolic space and bind to troponin C (TNNC1), resulting in the release of inhibition induced by troponin I (TNNI1), which activates the sliding of thin and thick filaments, and lead to cardiac contraction. Recovery occurs as Ca2+ is extruded by the Na2+/Ca2+ exchanger (NCX1) and returned to the SR by the sarco(endo)plasmic Ca2+-ATPase (ATP2A2) pumps on the nonjunctional region of the SR that are regulated by phospholamban (PLN). This process is conserved in iPSC-CMs, but major differences exist, such as a nascent SR, the presence of an Inositol 1,4,5-trisphosphate (IP3)-releasable Ca2+ pool, and the complete absence of T-tubules. The genes encoding the major transmembrane ion channels involved in the generation of action potential are also shown. B) Immunofluorescence staining of cardiac troponin T and a-sarcomeric actinin in iPSC-CMs. C) Line-scan images and spontaneous Ca2+ transients in iPSC-CMs. KCNIP2: Potassium channel-interacting protein 2; KCNH2: Potassium voltage-gated channel, subfamily H (eag-related), member 2; KCNQ1: Potassium voltage-gated channel, KQT-like subfamily, member 1; NCX1: Na+/Ca2+ exchanger; KCNJ2: Potassium inwardly-rectifying channel, subfamily J, member 2; RYR2: Ryanodine receptor 2; SERCA2: ATPase, Ca2+ transporting, cardiac muscle, slow twitch 2; PLN: Phospholamban; CACNA1C; Calcium channel, voltage-dependent, L type, alpha 1C subunit; SCN5A: Sodium channel, voltage-gated, type V, alpha subunit; TNNT2: Troponin T type 2; MYL2: Myosin, light chain 2; MYL3: Myosin, light chain 3; TNNI3: Troponin I type 3; TNNC: Troponin C type 1; TTN: Titin; MYH6: Myosin, heavy chain 6, alpha; MYH7: Myosin, heavy chain 7, beta; MYBPC3: Myosin binding protein C; TPM1: Tropomyosin 1 (alpha); ACTC1: Actin, alpha, cardiac muscle 1.
Figure 3
Figure 3. Comparison of action potentials of ventricular-like iPSC-CMs and adult ventricular cardiomyocytes
Schematic of ventricular action potentials. Phases 0–4 are the rapid upstroke, early repolarization, plateau, late repolarization, and diastole, respectively. The ionic currents and the genes that generate the currents with schematics of the current trajectories are shown above and below the action potentials. For individual ion channel currents, the voltage dependence of channel-gating properties of ventricular-like iPSC-CMs is remarkably analogous to adult ventricular cardiomyocytes, but significant differences also exist, such as reduced or absence of inward rectifier K+ currents (IK1) and the presence of prominent pacemaker currents that contribute to their automaticity.

References

    1. Collins FS, Varmus H. A new initiative on precision medicine. The New England Journal of Medicine. 2015 - PMC - PubMed
    1. Houser SR, Margulies KB, Murphy AM, Spinale FG, Francis GS, Prabhu SD, Rockman HA, Kass DA, Molkentin JD, Sussman MA, Koch WJ, American Heart Association Council on Basic Cardiovascular Sciences CoCC, Council on Functional G, Translational B Animal models of heart failure: A scientific statement from the american heart association. Circulation Research. 2012;111:131–150. - PubMed
    1. Dixon JA, Spinale FG. Large animal models of heart failure: A critical link in the translation of basic science to clinical practice. Circulation. Heart failure. 2009;2:262–271. - PMC - PubMed
    1. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–872. - PubMed
    1. Burridge PW, Keller G, Gold JD, Wu JC. Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell. 2012;10:16–28. - PMC - PubMed

Publication types

MeSH terms